SEER
Seer, Inc.
NasdaqGS Healthcare United States
2,17 $US
-1.81% today
+19.23% YTD · -6.06% 1Y
1
Insider transactions
SEC Form 4 · AMF · BaFin — rolling 90 days
15
Hedge funds tracked
Latest available SEC 13F filings
59
/ 100
MIXED

Analysis Seer, Inc. (SEER) — Kairos Score 59/100

Composite score aggregating 8 smart money dimensions: insiders (SEC/AMF/BaFin), hedge funds, politicians & gurus, price momentum, valuation, analyst consensus, financial health, earnings momentum. The higher the score, the more favorable the institutional signals consensus.

💡 Detailed breakdown (the 8 sub-scores) available in the Premium dashboard.

About Seer, Inc.

Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Key info

👔
CEO
Dr. Omid C. Farokhzad M.D., Ph.D.
📍
HQ
3800 Bridge Parkway, Suite 102, Redwood City, CA, 94065, United States
👥
Employees
124
💰
Market cap
120 157 280,00 $US
💸
Dividend yield
0.00%

🕴️ Insider activity (90 days)

1 transactions — 0 buys and 1 sales reported by Seer, Inc. executives.

HD
Horn David R.
PRESIDENT & CFO · 2026-08-18
Sell

🏦 Hedge Funds

15 institutional funds report a position on SEER in their latest SEC quarterly filing.

VANGUARD GROUP INC
VANGUARD CAPITAL MANAGEMENT LLC
BlackRock, Inc.
RENAISSANCE TECHNOLOGIES LLC
CITADEL ADVISORS LLC

📰 Recent news

15 recent articles on SEER.

🧠 What makes Kairos Insider

Beyond raw data, we aggregate and score every smart money signal to give you a unique view.

🧠

Kairos Score 0-100

8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.

🎯

Insider Clusters

Detection of clustered purchases or sales by several executives in the same stock.

🏦

13F Hedge Funds

Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.

📈

ETF Rotations

NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.

🔥

Google Trends

Spot marked changes in search interest around the stocks being followed.

📧

Email alerts

Create your watchlist and receive a brief of events affecting your tickers.

Companies in the same sector as Seer, Inc.

Official sources · Public data · SEC EDGAR — Form 4 & 13F · AMF — Executive filings · BaFin — Directors' Dealings · Yahoo Finance · Alpha Vantage

🔓 Unlock the full analysis

This public page only shows a preview. The full analysis of SEER on the Kairos Insider dashboard includes:

✅ Full Kairos Score (8-axis radar + synthesis)
✅ History of all 1 insider transactions over 90 days
✅ All 15 detected institutional funds
✅ Thematic ETFs (ARK, BUZZ, NANC, GOP, JEPI…)
✅ Hot Stocks Google Trends
✅ Available history: AUM + rotations
✅ Fundamentals (P/E, PEG, EV/EBITDA, ROE…)
✅ Financial health (Altman Z, Piotroski F)
✅ Sector peers + recent earnings
See full analysis →
Analyze other tickers for free →

Free signup · Pro €19/month or €190/year